190 likes | 378 Views
Kilimanjaro Christian Medical Centre Moshi, Tanzania. Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania. Florida J. Muro , Suzanne P. Fiorillo , Christopher Odhiambo , Coleen K. Cunningham, Ann M. Buchanan KCMC-Duke Collaboration Moshi Tanzania
E N D
Kilimanjaro Christian Medical Centre • Moshi, Tanzania Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K. Cunningham, Ann M. Buchanan KCMC-Duke Collaboration Moshi Tanzania XIX International AIDS Conference, Washington, DC 24 July 2012
Background • More than 350 million people worldwide are infected with hepatitis B virus (HBV), 170 million with hepatitis C virus (HCV) • HBV and HCV are more prevalent among HIV-infected individuals • HIV increases the speed of liver dysfunction among those with co-infection • Liver disease due to chronic hepatitis: increasing cause of morbidity and mortality among those with HIV
Background • Chronic HBV infection risk: • up to a 90% risk with perinatal infection • 25-30% risk with early childhood infection • < 5% risk among adults • HCV infection: chronic infection in 75-80% of adults • Data on hepatitis-HIV co-infection among African populations are scarce
Background • Three phases of chronic HBV infection: Children are typically in the immune tolerant phase.
Objective • To determine Hepatitis B and Hepatitis C prevalence in healthy HIV-negative and HIV-infected children in Kilimanjaro Region, Tanzania
Methods • Banked serum/plasma samples • HIV-uninfected, healthy children: 1 month -18 years • N=385 • HIV-infected children on HAART, 1-16 years • N=158 • HBV testing: • Hepatitis B surface ag (HBsAg) • Hepatitis B core antibody (HBcAb) • Hepatitis B surface antibody (HBsAb) • Study Location: Moshi, Kilimanjaro Region, • Tanzania, East Africa
Methods • HCV testing: • Anti-HCV ELISA • Validation studies performed on all assays prior to use • All assays FDA-approved • Definitions: • Any prior HBV infection: HBcAb or HBsAg + • Presumptive chronic HBV infection: HBsAg + at time of test
Results • 543 serum/plasma samples tested • 385 HIV-negative • 158 HIV-infected • Evidence of any HBV infection: 4.2% (95% CI: 2.5, 5.9) • Among HIV-negative children: 2.1% (95% CI: 0.6, 3.5) • Among HIV-infected children: 9.5% (95% CI 4.9, 14.1)
Results Children with HIV infection were more likely to have evidence of HBV infection than HIV-negative children: OR 4.9 (95% CI 2.1, 11.9) p < 0.0001
Results • *These 2 patients were HBcAb and HBsAb positive, likely reflecting maternal antibody transmission
Results • Prevalence of presumed chronic HBV infection: 3.0% (1.6, 4.5) • Among HIV-negative children: 1.3% (0.2, 2.5) • Among HIV-infected children: 7.5% (3.2, 11.9) • Resolved infection (HBcAb and HBsAb positive) was found in 5 patients: 2 HIV-infected and 3 HIV-negative • Isolated HBcAb was found in two patients • Hepatitis C: 541 samples tested by anti-HCV ELISA • 0.0%
Results N=44
Conclusions • HCV was not found in this large pediatric cohort • HBV prevalence is high among HIV-infected children in the Kilimanjaro Region of Tanzania • Children with HIV are almost 5 times as likely to show evidence of infection than children without HIV
Conclusions • The prevalence of chronic HBV-HIV co-infection in this population (7.5%) is higher than that reported recently in many other pediatric populations: • 3.3% Thailand • 4.9% China • 4% Kenya • 1.2% Dar es Salaam, Tanzania • Though lower than some other African countries: • Nigeria (7.7%) • Namibia (8.7%) • Ivory Coast (12.1%)
Conclusions • High prevalence of HIV-HBV co-infection in this pediatric population • Need for routine HBsAg screening of all HIV-infected children • Prior to HAART initiation • More comprehensive prevalence data needed – across all age groups • Prevention of HBV could be strengthened by wider vaccination coverage • Vaccinate high risk children • Birth dose?
Limitations • Chronic hepatitis B could not be confirmed • Samples tested at a single timepoint • Larger sample size needed to determine true prevalence of HIV-HBV co-infection among children in this region • The significance of isolated HBcAb in two patients is unclear • No measurement of HBV DNA
Further Study • Follow up study planned for a larger prospective study of HIV-infected children • Unanswered questions: • Best treatment options for HIV-HBV infected children? • Already on HAART? • Immune tolerant disease • Immune active disease • Initiating HAART? • Immune tolerant disease • Immune active disease
Acknowledgements • Co-authors: Florida Muro, Chris Odhiambo, Suzanne Fiorillo, Coleen Cunningham • Duke University Center for AIDS Research (CFAR) • 2010 developmental grant (5P30 AI064518) (AM Buchanan) • Duke Global Health Institute • Transition Award (FJ Muro) • Kilimanjaro Christian Medical Centre Leadership • Patients and families in the Kilimanjaro Region